X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ZKAB001 (Socazolimab) (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories.
Lead Product(s): Socazolimab,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: ZKAB001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
The initiation of this Phase 3 trial is based on the very encouraging results from an earlier Phase Ib trial in which Socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with extensive-stage small-cell lung cancer.
Lead Product(s): Socazolimab,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: ZKAB001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2021
Details:
Indian Institute of Chemical Technology, (IICT) and Lee Pharma have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Lee Pharma would file the application for getting the approval from DCGI and will manufacture the drug.
Lead Product(s): 2-Deoxy-D-Glucose
Therapeutic Area: Infections and Infectious Diseases Product Name: 2-DG
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: CSIR-Indian Institute of Chemical Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
